The latest financial statement is for the year ending 2025-12-31.
| Cash Flow | 2025-12-31 |
|---|---|
| Net loss | -6,009,520 |
| Non-cash lease expense for right-of-use asset | 61,695 |
| Stock-based compensation expense | 1,388,322 |
| Common stock issued for services | 171,611 |
| Realized loss on digital assets | 904,394 |
| Prepaid insurance | 5,784 |
| Other prepaid expenses | -40,828 |
| Accounts payable and accrued expenses | 380,776 |
| Research and development contract liabilities | -2,940 |
| Net cash used in operating activities | -3,070,618 |
| Purchase of digital assets | 2,637,360 |
| Cash paid for liora investment | 440,000 |
| Capitalized transaction costs | 95,102 |
| Net cash used in investing activities | -3,172,462 |
| Proceeds from sale of securities in registered direct offerings, net of offering costs | 6,087,037 |
| Proceeds from sale of securities in registered private placement, net of offering costs | 4,178,162 |
| Exercise of common stock warrants | 45,801 |
| Net cash provided by financing activities | 10,311,000 |
| Net change in cash | 4,067,920 |
| Cash - beginning of period | 1,038,952 |
| Cash - end of period | 5,106,872 |
LIXTE BIOTECHNOLOGY HOLDINGS, INC. (LIXT)
LIXTE BIOTECHNOLOGY HOLDINGS, INC. (LIXT)